CSF-1R inhibitor tyrosine kinase pexidartinib is the first approved systemic therapy for patients with tenosynovial giant cell tumors; however, it may cause potentially life-threatening mixed or cholestatic hepatotoxicity [29]. The gene discussed is CSF1R; the disease is tenosynovial giant cell tumor.